Chemokines and cytokines in patients with an occult Onchocerca volvulus infection

Microbes and Infection

Volumn 14, Issue 5, 2012, Pages 438-446

  Lechner, Christian J ^a,b   Gantin, Richard G ^b   Seeger, Tanja ^a   Sarnecka, Alicja ^a   Portillo, Jennifer ^a   Schulz Key, Hartwig ^a,b   Karabou, Potochoziou K ^c   Helling Giese, Gertrud ^a,b   Heuschkel, Christoph ^a,b   Banla, Meba ^b,d   Soboslay, Peter T ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Onchocerciasis Research Laboratories   (Togo)

^c National Onchocerciasis Control Programme   (Togo)

^d UNIVERSITÉ DE LOMÉ   (Togo)

Author keywords

Antibody; Chemokine; Cytokine; Immune response; Infection; Onchocerca volvulus

Indexed keywords

CHEMOKINE; CHEMOKINE CCL23; CINTREDEKIN BESUDOTOX; CXCL13 CHEMOKINE; CYTOKINE; EOTAXIN 2; INTERLEUKIN 8; IVERMECTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PLACEBO; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EOSINOPHIL; FEMALE; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MICROFILARIA; MONOCYTE; NONHUMAN; ONCHOCERCIASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TH2 CELL;

ADULT; ANIMALS; ANTHELMINTICS; CYTOKINES; FEMALE; HUMANS; IVERMECTIN; MALE; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; SERUM;

FILARIA; ONCHOCERCA VOLVULUS;

EID: 84859433937     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2011.12.002     Document Type: Article

References (51)

1. Sékétéli A., Adeoye G., Eyamba A., Nnoruka E., Drameh P., Amazigo U.V., Noma M., Agboton F., Aholou Y., Kale O.O., Dadzie K.Y. The achievements and challenges of the African Programme for Onchocerciasis Control (APOC). Ann. Trop. Med. Parasitol. 2002, 96(Suppl. 1):S15-S28.
2. Winnen M., Plaisier A.P., Alley E.S., Nagelkerke N.J., van Oortmarssen G., Boatin B.A., Habbema J.D. Can ivermectin mass treatments eliminate onchocerciasis in Africa?. Bull. World Health Organ. 2002, 80:384-391.
3. Amazigo U., Okeibunor J., Matovu V., Zouré H., Bump J., Sékétéli A. Performance of predictors: evaluating sustainability in community-directed treatment projects of the African programme for onchocerciasis control. Soc. Sci. Med. 2007, 64:2070-2082.
4. Boatin B. The Onchocerciasis Control Programme in West Africa (OCP). Ann. Trop. Med. Parasitol. 2008, 102(Suppl. 1):13-17.
5. Diawara L., Traoré M.O., Badji A., Bissan Y., Doumbia K., Goita S.F., Konaté L., Mounkoro S., Sarr M.D., Seck A.F., Toé L., Tourée S., Remme J.H. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl. Trop. Dis. 2009, 3:e497.
6. Greene B.M., Taylor H.R., Cupp E.W., Murphy R.P., White A.T., Aziz M.A., Schulz-Key H., D'Anna S.A., Newland H.S., Goldschmidt L.P., et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N. Engl. J. Med. 1985, 313:133-138.
7. Dadzie K.Y., Bird A.C., Awadzi K., Schulz-Key H., Gilles H.M., Aziz M.A. Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis. Br. J. Ophthalmol. 1987, 71:78-85.
8. Chavasse D.C., Post R.J., Lemoh P.A., Whitworth J.A. The effect of repeated doses of ivermectin on adult female Onchocerca volvulus in Sierra Leone. Trop. Med. Parasitol. 1992, 43:256-262.
9. Kläger S.L., Whitworth J.A., Downham M.D. Viability and fertility of adult Onchocerca volvulus after 6 years of treatment with ivermectin. Trop. Med. Int. Health 1996, 1:581-589.
10. Awadzi K., Attah S.K., Addy E.T., Opoku N.O., Quartey B.T. The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients. Trans. R. Soc. Trop. Med. Hyg. 1999, 93:189-194.
11. Partono F. The spectrum of disease in lymphatic filariasis. Ciba Found. Symp. 1987, 127:15-31.
12. Dimock K.A., Eberhard M.L., Lammie P.J. Th1-like antifilarial immune responses predominate in antigen-negative persons. Infect. Immun. 1996, 64:2962-2967.
13. Soboslay P.T., Geiger S.M., Weiss N., Banla M., Lüder C.G., Dreweck C.M., Batchassi E., Boatin B.A., Stadler A., Schulz-Key H. The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection. Immunology 1997, 90:592-599.
14. Timmann C., Abraha R.S., Hamelmann C., Buttner D.W., Lepping B., Marfo Y., Brattig N., Horstmann R.D. Cutaneous pathology in onchocerciasis associated with pronounced systemic T-helper 2-type responses to Onchocerca volvulus. Br. J. Dermatol. 2003, 149:782-787.
15. Soboslay P.T., Lüder C.G., Hoffmann W.H., Michaelis I., Helling G., Heuschkel C., Dreweck C.M., Blanke C.H., Pritze S., Banla M., et al. Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection. Clin. Exp. Immunol. 1994, 96:238-244.
16. Mai C.M., Hamm D.M., Banla M., Agossou A., Schulz-Key H., Heuschkel C., Soboslay P.T. Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy. Clin. Exp. Immunol. 2007, 147:504-512.
17. Mahanty S., Luke H.E., Kumaraswami V., Narayanan P.R., Vijayshekaran V., Nutman T.B. Stage-specific induction of cytokines regulates the immune response in lymphatic filariasis. Exp. Parasitol. 1996, 84:282-290.
18. Hoerauf A., Brattig N. Resistance and susceptibility in human onchocerciasis-beyond Th1 vs. Th2. Trends Parasitol. 2002, 18:25-31.
19. Mutapi F., Winborn G., Midzi N., Taylor M., Mduluza T., Maizels R.M. Cytokine responses to Schistosoma haematobium in a Zimbabwean population: contrasting profiles for IFN-gamma, IL-4, IL-5 and IL-10 with age. BMC Infect. Dis. 2007, 7:139.
20. Cooper P.J., Guderian R.H., Prakash D., Remick D.G., Espinel I., Nutman T.B., Taylor D.W., Griffin G.E. RANTES in onchocerciasis: changes with ivermectin treatment. Clin. Exp. Immunol. 1996, 106:462-467.
21. Cooper P.J., Beck L.A., Espinel I., Deyampert N.M., Hartnell A., Jose P.J., Paredes W., Guderian R.H., Nutman T.B. Eotaxin and RANTES expression by the dermal endothelium is associated with eosinophil infiltration after ivermectin treatment of onchocerciasis. Clin. Immunol. 2000, 95:51-61.
22. Fendt J., Hamm D.M., Banla M., Schulz-Key H., Wolf H., Helling-Giese G., Heuschkel C., Soboslay P.T. Chemokines in onchocerciasis patients after a single dose of ivermectin. Clin. Exp. Immunol. 2005, 142:318-326.
23. Souza A.L., Sousa-Pereira S.R., Teixeira M.M., Lambertucci J.R., Teixeira A.L. The role of chemokines in Schistosoma mansoni infection: insights from human disease and murine models. Mem. Inst. Oswaldo Cruz 2006, 101:333-338.
24. Ramesh M., Paciorkowski N., Dash Y., Shultz L., Rajan T.V. Acute but not chronic macrophage recruitment in filarial infections in mice is dependent on C-C chemokine ligand 2. Parasite Immunol. 2007, 29:395-404.
25. Yaméogo L. Special intervention zones. Ann. Trop. Med. Parasitol. 2008, 102(Suppl. 1):23-24.
26. Awissi D., Heuschkel C., Banla M., Schulz-Key H. Ivermectin in the treatment of onchocerciasis: feasibility, compliance and efficacy of a mass treatment. Bull. Soc. Pathol. Exot. 1991, 84:739-749.
27. Schulz-Key H. The collagenase technique: how to isolate and examine adult Onchocerca volvulus for the evaluation of drug effects. Trop. Med. Parasitol. 1988, 39(Suppl. 4):423-440.
28. Greene B.M., Fanning M.M., Ellner J.J. Non-specific suppression of antigen-induced lymphocyte blastogenesis in Onchocerca volvulus infection in man. Clin. Exp. Immunol. 1983, 52:259-265.
29. Akuffo H., Maasho K., Lavebratt C., Engström K., Britton S. Ivermectin-induced immunopotentiation in onchocerciasis: recognition of selected antigens following a single dose of ivermectin. Clin. Exp. Immunol. 1996, 103:244-252.
30. Greene B.M., Taylor H.R., Aikawa M. Cellular killing of microfilariae of Onchocerca volvulus: eosinophil and neutrophil-mediated immune serum-dependent destruction. J. Immunol. 1981, 127:1611-1618.
31. Galioto A.M., Hess J.A., Nolan T.J., Schad G.A., Lee J.J., Abraham D. Role of eosinophils and neutrophils in innate and adaptive protective immunity to larval Strongyloides stercoralis in mice. Infect. Immun. 2006, 74:5730-5738.
32. Ramalingam T., Rajan B., Lee J., Rajan T.V. Kinetics of cellular responses to intraperitoneal Brugia pahangi infections. Infect. Immun. 2003, 71:4361-4367.
33. Satapathy A.K., Sartono E., Sahoo P.K., Dentener M.A., Michael E., Yazdanbakhsh M., Ravindran B. Human bancroftian filariasis: immunological markers of morbidity and infection. Microbes Infect. 2006, 8:2414-2423.
34. Ying S., Robinson D.S., Meng Q., Barata L.T., McEuen A.R., Buckley M.G., Walls A.F., Askenase P.W., Kay A.B. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J. Immunol. 1999, 163:3976-3984.
35. Pearlman E., Toé L., Boatin B.A., Gilles A.A., Higgins A.W., Unnasch T.R. Eotaxin expression in Onchocerca volvulus-induced dermatitis after topical application of diethylcarbamazine. J. Infect. Dis. 1999, 180:1394-1397.
36. Taylor H.R., Greene B.M., Langham M.E. Controlled clinical trial of oral and topical diethyl-carbamazine in treatment of onchocerciasis. Lancet 1980, 1:943-946.
37. Deshmane S.L., Kremlev S., Amini A., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 2009, 29:313-326.
38. Rojas-Ramos E., Avalos A.F., Pérez-Fernandez L., Cuevas-Schacht F., Valencia-Maqueda E., Terán L.M. Role of the chemokines RANTES, monocyte chemotactic proteins-3 and -4, and eotaxins-1 and -2 in childhood asthma. Eur. Respir. J. 2003, 22:310-316.
39. Dogan R.N., Karpus W.J. Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation. Front. Biosci. 2004, 9:1500-1505.
40. Strieter R.M., Gomperts B.N., Keane M.P. The role of CXC chemokines in pulmonary fibrosis. J. Clin. Invest. 2007, 117:549-556.
41. Braunersreuther V., Mach F., Steffens S. The specific role of chemokines in atherosclerosis. Thromb. Haemost. 2007, 97:714-721.
42. Lukacs N.W., Kunkel S.L., Strieter R.M., Chensue S.W. The role of chemokines in Schistosoma mansoni granuloma formation. Parasitol. Today 1994, 10:322-324.
43. Endara P., Vaca M., Chico M.E., Erazo S., Oviedo G., Quinzo I., Rodriguez A., Lovato R., Moncayo A.L., Barreto M.L., Rodrigues L.C., Cooper P.J. Long-term periodic anthelmintic treatments are associated with increased allergen skin reactivity. Clin. Exp. Allergy 2010, 40:1669-1677.
44. Allen J.E., Loke P. Divergent roles for macrophages in lymphatic filariasis. Parasite Immunol. 2001, 23:345-352.
45. Babu S., Kumaraswami V., Nutman T.B. Alternatively activated and immunoregulatory monocytes in human filarial infections. J. Infect. Dis. 2009, 199:1827-1837.
46. Semnani R.T., Mahapatra L., Moore V., Sanprasert V., Nutman T.B. Functional and phenotypic characteristics of alternative activation induced in human monocytes by interleukin-4 or the parasitic nematode Brugia malayi. Infect. Immun. 2011, 79:3957-3965.
47. Adjobimey T., Hoerauf A. Induction of immunoglobulin G4 in human filariasis: an indicator of immunoregulation. Ann. Trop. Med. Parasitol. 2010, 104:455-464.
48. Lee J.S., Kim I.S. Leukotactin-1/CCL15 induces cell migration and differentiation of human eosinophilic leukemia EoL-1 cells through PKCdelta activation. Mol. Biol. Rep. 2010, 37:2149-2156.
49. Kalayci O., Sonna L.A., Woodruff P.G., Camargo C.A., Luster A.D., Lilly C.M. Monocyte chemotactic protein-4 (MCP-4; CCL-13): a biomarker of asthma. J. Asthma 2004, 41:27-33.
50. Garcia-Zepeda E.A., Combadiere C., Rothenberg M.E., Sarafi M.N., Lavigne F., Hamid Q., Murphy P.M., Luster A.D. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J. Immunol. 1996, 157:5613-5626.
51. Pivarcsi A., Homey B. Chemokine networks in atopic dermatitis: traffic signals of disease. Curr. Allergy Asthma Rep. 2005, 5:284-290.